Previous Close | 157.23 |
Open | 156.87 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 155.38 - 157.53 |
52 Week Range | 136.10 - 171.30 |
Volume | 103,792 |
Avg. Volume | 222,541 |
Net Assets | 8.07B |
NAV | 153.27 |
PE Ratio (TTM) | 64.54 |
Yield | 1.28% |
YTD Return | -0.16% |
Beta (3y) | 0.97 |
Expense Ratio (net) | 0.10% |
Inception Date | 2004-01-26 |
When it comes to assessing the cost of a retirement mutual fund or exchange-traded fund, most investors simply look at the absolute value of the expense ratio. The lower the expense ratio, they figure, the better. For some ETFs and funds, the definition of low-cost retirement funds is relative.
Analyzing Johnson & Johnson’s Stock and Valuations in March 2018
What Analysts Recommend for Merck in March 2018
How Ionis Pharmaceuticals Is Positioned in 2018
Here are several smart ways to invest in the companies that keep people healthy.
An Overview of Pfizer's 4Q17: What Lies Ahead?
Changes in Johnson & Johnson's Valuation in February 2018
What's Next for Abbott Laboratories after a Stellar 2017?
A Preview of Eli Lilly’s 4Q17 Earnings Release on January 31A look at Eli Lilly & Co.
Pfizer’s (PFE) business is classified into two business segments—the Innovative Health segment and Essential Health segment. The products that are expected to contribute towards Pfizer’s revenue growth include Eliquis, Sulperazon, Lipitor, Chantix/Champix, Lyrica IH, Xalkori, Xeljanz, Celebrex, Medrol, and Xtandi. The above chart compares the revenues for Pfizer’s key growth contributors in the past few quarters.
The solid performance of the healthcare market in 2017 has created investment opportunities. These ETFs are poised to take advantage.
Arrowhead Pharmaceuticals: A Promising Drug Pipeline
Who’s Watching Merck & Co. in January 2018?
Johnson & Johnson’s 4Q17 Earnings on January 23: What to Expect
In December 2016, the U.S. Attorney’s Office for the District of Massachusetts issued an indictment against six former Insys (INSY) employees, which included the company’s former president, CEO, and director Michael Babich. This indictment was on charges including racketeering conspiracy, conspiracy to commit mail fraud, conspiracy to commit wire fraud, and conspiracy to violate the anti-kickback statute.
How Is Accelerate Diagnostics Positioned at the Start of 2018?
Vanguard continues to set the bar as far as low-cost mutual funds and ETFs. Low-cost is almost synonymous with its brand. When it comes to retirement, Vanguard ETF choices hold even more sway over investors, as they should.
One of the ways subscribers to my stock and options advisory newsletter, The Liberty Portfolio, generate additional monthly income is by using naked puts. By selling puts, you choose a stock you either own or might want to buy. You sell the right for someone else to put the stock to you, that is, force you to buy it, at a particular price (strike price) on or before a particular date (expiration date).
Healthcare ETFs saw plenty of fireworks in 2017, thanks in large part to Congress.
New Insights for Incyte Corporation as of January
The healthcare sector was one of the best-performing sectors in the S&P 500 last year. Investors looking for more of the same this year can consider an array of exchange traded funds dedicated to the sector, ...
Vanguard Health Care ETF (NYSEARCA:VHT) was up an impressive 21% this past year, besting the S&P 500 and running close to the Dow Jones Industrial Average for the past 12 months. The point is, healthcare was a tough way to make a 20% gain last year, yet VHT did it and it paid a 1.6% dividend in the process. The VHT ETF is set up to track the MSCI US Investable Market Health Care 25/50 Index.
In 3Q17, Merck’s (MRK) Januvia generated revenue of ~$1.0 billion which reflected ~1% growth YoY (year-over-year) and ~7% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Januvia ...
The solid performance of the healthcare market in 2017 has created investment opportunities. These ETFs are poised to take advantage.
Eli Lilly’s (LLY) human pharmaceutical business reported revenues of $5.0 billion in 2Q17, an 11.0% rise compared to $4.5 billion in 2Q16.